Immune checkpoint blockers and ovarian cancer
Although the idea, called “cancer immunotherapy,” is very appealing and has previously been shown to work in several mouse models of cancer, it has in general been very difficult to translate cancer immunotherapy approaches to humans. Because of this frustration, by the 1990s, many scientists and bi...
Saved in:
| Main Author: | Chinmoy K Bose |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2017-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2017;volume=38;issue=2;spage=182;epage=189;aulast=Bose |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research progress of immune checkpoint inhibitors in ovarian cancer
by: Lingli Zhao, et al.
Published: (2024-12-01) -
PD-1 and LAG-3 were optimal combination of immune checkpoints for predicting poor clinical outcomes of patients with ovarian cancer
by: Yifan Wu, et al.
Published: (2025-08-01) -
The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors
by: Baoyue Pan, et al.
Published: (2025-08-01) -
Immune checkpoint blockades in gynecological cancers: A review of clinical trials
by: Hongling Peng, et al.
Published: (2022-09-01) -
Stemness-driven clusters in ovarian cancer: immune characteristics and prognostic implications
by: Xinyan Zeng, et al.
Published: (2025-06-01)